StockMarketWire.com - Respiratory diseases focused Verona Pharma said positive trial data on a treatment for chronic obstructive pulmonary disease had been published in peer reviewed journal Respiratory Research.

The study met its primary endpoint, demonstrating that ensifentrine produced clinically and statistically significant improvements in lung function at all doses.


At 9:54am: [LON:VRP] Verona Pharma PLC share price was +1.5p at 64p



Story provided by StockMarketWire.com